Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients with Stable Heart Failure using Olmesarta
Not Applicable
- Conditions
- Chronic Heart Failure
- Registration Number
- JPRN-UMIN000000561
- Lead Sponsor
- Tohoku Heart Failure Association The SUPPORT Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have renal dysfunction (serum creatinine >=3.0mg/dL) or those who are receiving chronic hemodialysis. 2)History of drug hypersensitivity to olmesartan. 3)Patients who have severe liver dysfunction. 4)History of angioedema. 5)History of malignant tumor or life-threatening illness of poor prognosis. 6)Pregnant or possibly pregnant patients. 7)Cardiovascular surgery within 6months prior to the date of the entry. 8)Acute myocardial infarction within 6 months prior to the date of the entry. 9)Percutaneous coronary intervention or stent implantation within 6 months prior to the date of the entry. 10)Other patients deemed unsuitable as subjects of the study by the treating physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method